Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA Takes Aim At Valeant In Defense Of Drug Pricing By ‘Innovative’ Firms

Executive Summary

The strategy of publicly criticizing pharmaceutical companies, albeit non-members, is an unusual one for PhRMA. But it demonstrates the group’s interest in playing offense, and not just defense, in the drug price debate.

You may also be interested in...



At Drug Pricing Hearing, Innovator Companies Mainly Escape Congressional Wrath

Members of House Oversight Committee accuse Turing and Valeant of 'trashing' mainstream innovator companies with their drug pricing practices.

Pharma's Love Affair With Dealmaking: No End In Sight

The pace of pharma dealmaking continued unabated in 2015, climaxing with Pfizer’s agreed $160 billion merger with Allergan. Conditions are right for this situation to persist, at least for the foreseeable future.

Mylan Joins Firms Facing DOJ Probe On Price Hikes; Senate Plans Industry-Free Hearing

Senate Special Aging Committee hearing Wednesday to focus on price spikes in off-patent drugs without testimony from drug makers.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS057217

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel